PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Growing Demand for Inexpensive - Effective Drugs and Continuing Patent Expiries Provide Growth Prospects for the EU Generics Market - New analysis from Frost & Sullivan, Blockbusters Going off Patent - Opportunities for Generics, finds that the European generics market earned revenues of $17.18 billion in 2006 and estimates this to reach $35.90 billion in 2013
Growing Demand for Inexpensive - Effective Drugs and Continuing Patent Expiries Provide Growth Prospects for the EU Generics Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/07/12 - New analysis from Frost & Sullivan, Blockbusters Going off Patent - Opportunities for Generics, finds that the European generics market earned revenues of $17.18 billion in 2006 and estimates this to reach $35.90 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With an ageing population and expensive drugs driving healthcare costs upwards, generic medicines are gaining significance in Europe. The governments are under tremendous pressure to reduce healthcare expenditure. In this scenario, generics are widely regarded as the best method to allow access to safe, effective and high quality drugs at affordable prices to a vast majority of patients.

New analysis from Frost & Sullivan (pharma.frost.com), Blockbusters Going off Patent - Opportunities for Generics, finds that the European generics market earned revenues of $17.18 billion in 2006 and estimates this to reach $35.90 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the Opportunities for Generics as blockbusters going off patent, send an e-mail to Radhika Menon Theodore, Corporate Communications at rmtheodore[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the information through email upon receipt of the above information.

“Patent expiries, pro-generic reforms in certain countries and need for cheap, effective medicines are the key factors driving growth in the European generics market,” notes Frost & Sullivan Research Analyst Sumanth Kambhammettu. “Various studies have indicated the cost savings obtained from generics and several governments in Europe are actively promoting generics.”

In addition, with a number of blockbusters expected to lose patent exclusivity in the next five to seven years, there are significant growth opportunities for generics in Europe. Certain countries in the region offer incentives to pharmacists and physicians for prescribing generics and this is likely to have a huge impact on the generics market.

On the other hand, generic manufacturers will have to combat hurdles such as severe pricing pressures, reference pricing, parallel trading and strategies adopted by ethical pharmaceutical companies such as evergreening and re-formulation.

“Several countries have resorted to methods such as generic substitution and reference pricing to lower pharmaceutical pricing, which are expected to result in restricted profit margins,” explains Kambhammettu. “Moreover, the strategies of ethical pharmaceutical companies to extend the patent life-cycle of their products are also expected to pose a serious problem in the long-term.”

Generics market participants will increasingly aim to leverage low cost contract manufacturing facilities in countries such as India and China to speed their time to market. Strategic agreements between participants operating in different countries are also expected to provide synergistic benefits. Finally, market participants will need to focus on optimising their product portfolio and devising long-term R&D strategies to ensure success in a competitive environment.

Blockbusters Going off Patent - Opportunities for Generics is part of the Pharmaceutical and Biotechnology Growth Partnership Service, which also includes research on the world stem cell therapeutics markets and the pricing and reimbursement issues for generics and biosimilars in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Growing Demand for Inexpensive - Effective Drugs and Continuing Patent Expiries Provide Growth Prospects for the EU Generics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Radhika Menon Theodore 
+91 44 42044541 rmtheodore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)